Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
In participants with nonrelapsing secondary progressive multiple sclerosis, the risk of disability progression was lower among those who received treatment with tolebrutinib than among those who received placebo. (Funded by Sanofi; HERCULES ClinicalTrials.gov number, NCT04411641.).
Authors
- Gavin Giovannoni (ORCID: https://orcid.org/0000-0001-9995-1700)
- Wendy Vargas (ORCID: https://orcid.org/0000-0001-8512-048X)
- Sana Syed (ORCID: https://orcid.org/0000-0003-0954-0583)
- Daniel S. Reich (ORCID: https://orcid.org/0000-0002-2628-4334)
- Patrick Vermersch (ORCID: https://orcid.org/0000-0003-0997-8817)
- Robert J. Fox (ORCID: https://orcid.org/0000-0002-4263-3717)
- Anthony Traboulsee (ORCID: https://orcid.org/0000-0002-0351-9639)
- Erik Wallstroem
- Timothy J. Turner (ORCID: https://orcid.org/0000-0001-9770-2647)
- Celia Oreja‐Guevara (ORCID: https://orcid.org/0000-0002-9221-5716)
- Ye Li (ORCID: https://orcid.org/0000-0002-8647-384X)
- Amit Bar-Or (ORCID: https://orcid.org/0000-0001-7179-0335)
Institutions
- Universidad Complutense de Madrid (ES)
- National Institutes of Health (US)
- Cleveland Clinic (US)
- University of British Columbia (CA)
- Inserm (FR)
- Queen Mary University of London (GB)
- Université de Lille (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES)
- Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine (FR)
- National Institute of Neurological Disorders and Stroke (US)
- Sanofi (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1056/nejmoa2415988
- Citations
- 81
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 117.73
Funders
- Sanofi